PDCD1 and hepatocellular carcinoma: Furthermore, in a proof-of-concept trial (NCT03939975), of the 50 patients with advanced HCC who received anti-PD-1 inhibitor, 33 patients with stable disease or an atypical response to anti-PD-1-inhibitors received subtotal RFA or MWA.